Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene study aims to personalize diabetes treatment

NCT ID NCT01762046

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how inherited gene variants influence the body's response to two common type 2 diabetes medications, metformin and glipizide. Over 1,000 participants took each drug and had their glucose and insulin levels measured. The goal was to understand why some people respond better than others, which could lead to more personalized treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metformin and glipizide
What this could lead to
If successful, this could help doctors personalize diabetes treatment based on a person's genes.
What could go wrong
This is a completed early-phase study focused on understanding genetics, not testing a new treatment. Results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

1,033 people

The number who actually took part.

Started

Jan 2008

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or non-pregnant female \> 18 years of age * Investigators will target preferentially people at risk of diabetes or requiring diabetes meds * The first tier of risk will be illustrated by one of the following variables (e.g. established type 2 diabetes on diet therapy alone, elevated random glucose in electronic medical record, PCOS, metabolic syndrome, obesity, history of gestational diabetes, etc.) * The second tier of risk will be illustrated by other features that correlate with diabetes risk, such as a history of hypertension or dyslipidemia * Otherwise healthy subjects may also be candidates for the study. * Able and willing to give consent relevant to genetic investigation Exclusion Criteria: * Pregnant, nursing or at risk of becoming pregnant * Currently taking any medications for the treatment of diabetes * Currently on metformin for any other indication (e.g. PCOS) * Onset of diabetes in a family member before age 25, with autosomal transmission of diabetes across three generations * History of liver or kidney disease * Known severe allergic reactions to sulfonamides * History of porphyria * Documented estimated glomerular filtration rate (GFR) \< 60 ml/min/1.73 m2, based on the most recent serum creatinine measurement available in the electronic medical record, and calculated by the Modification of Diet in Renal Disease equation (49) available at http://www.nephron.com/cgi-bin/MDRD\_GFR.cgi * Currently taking medications known to affect glycemic parameters, such as glucocorticoids, growth hormone or fluoroquinolones * Planned radiologic or angiographic study requiring contrast within one week of completion of this study * Established coronary artery disease (CAD), defined as: * History of myocardial infarction. * History of revascularization (coronary artery bypass grafting, percutaneous coronary intervention (e.g. stenting or balloon angioplasty). * Evidence of ischemia on cardiac stress test. * Enrolled in any other interventional study at time of screening through completion of study protocol * History of bariatric surgery * History of seizures * History of stroke/CVA

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02116, United States

  • Joslin Diabetes Center

    Boston, Massachusetts, 02116, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.